With no adverse pathology, the critical prognostic indicator of biochemical recurrence is your PSA velocity. You won't be able to know that until you've had another PSA test. (I think a 3-month schedule is prudent, given the rise.) If you have another increase in PSA, and especially if the PSA velocity is greater than 0.05 ng/ml/year, it may be time for salvage radiation. If your PSA is stable, you can be comfortable just watching it.
If you should have another rise, you may be eligible to get in on a clinical trial of Decipherâ„¢ Genomic Classifier test which is very good at identifying patients who will
not progress to metastases (but is not as good in identifying those who will). It costs $4000 if you have to pay for it, but may be covered if you get it as part of the clinical trial. Check the list to see if any of the
locations are near to you:
/clinicaltrials.gov/ct2/show/NCT02080689- Allen